Skip to main content

ALX ONCOLOGY HOLDINGS INC

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

ALXO$1.11-13.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalIncome (Loss)DeficitEquity
Balance as of December 31, 202349,951,989$50$675,678$256$(486,272)$189,712
Issuance of common stock under equity incentive plans113,385—237——237
Issuance of common stock through ATM offering, net of commissions and offering costs of $0.1 million211,819—3,024——3,024
Stock-based compensation——7,031——7,031
Unrealized loss on available-for-sale investments———(228)—(228)
Net loss————(35,581)(35,581)
Balance as of March 31, 202450,277,19350685,97028(521,853)164,195
Issuance of common stock under equity incentive plans321,753—861——861
Issuance of common stock under employee stock purchase plan59,712—306——306
Issuance of common stock through ATM offering, net of commissions and offering costs of $0.8 million1,794,091226,201——26,203
Stock-based compensation——7,252——7,252
Unrealized loss on available-for-sale investments———(101)—(101)
Net loss————(39,399)(39,399)
Balance as of June 30, 202452,452,749$52$720,590$(73)$(561,252)$159,317
Issuance of common stock under equity incentive plans290,3551533——534
Issuance of common stock through ATM offering, net of commissions and offering costs——75——75
Stock-based compensation——6,952——6,952
Unrealized gain on available-for-sale investments———636—636
Net loss————(30,707)(30,707)
Balance as of September 30, 202452,743,104$53$728,150$563$(591,959)$136,807
Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
SharesAmountCapitalLossDeficitEquity
Balance as of December 31, 202240,861,386$41$589,735$(845)$(325,467)$263,464
Issuance of common stock under equity incentive plans1,663—————
Stock-based compensation——6,351——6,351
Unrealized gain on available-for-sale investments———757—757
Net loss————(30,184)(30,184)
Balance as of March 31, 202340,863,04941596,086(88)(355,651)240,388
Issuance of common stock under equity incentive plans76,210—112——112
Issuance of common stock under employee stock purchase plan52,920—338——338
Stock-based compensation——6,237——6,237
Unrealized loss on available-for-sale investments———(224)—(224)
Net loss————(34,159)(34,159)
Balance as of June 30, 202340,992,179$41$602,773$(312)$(389,810)$212,692
Issuance of common stock under equity incentive plans159,640—————
Stock-based compensation——6,964——6,964
Unrealized gain on available-for-sale investments———86—86
Net loss————(50,990)(50,990)
Balance as of September 30, 202341,151,819$41$609,737$(226)$(440,800)$168,752
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.